AI Analysis
Log in to generate an AI summary for this stock.
Log in to generate a MOAT report for this stock.
Log in to generate an earnings report for this stock.
Log in to generate an operating leverage report for this stock.
Log in to generate a management report for this stock.
Log in to generate a valuation report for this stock.
Telix Pharmaceuticals Limited
Video analysis: TLX
All videosNo video analysis for this stock yet. Request one from our team.
News: TLX
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
Telix Pharmaceuticals Limited (TLX) Presents at Morgan Stanley 24th Annual Global Healthcare Conference Transcript
FDA Approves Telix Pharmaceuticals Brain Cancer Imaging Drug
On Monday, the U.S. Food and Drug Administration (FDA) approved Pixclara (floretyrosine F18), an amino acid positron emission tomography (PET) imaging agent created by Telix Pharmaceuticals Limited (NASDAQ:TLX) to diagnose brain cancer.
FDA Approves Telix's Brain Cancer Imaging Drug Pixclara
MELBOURNE, Australia and INDIANAPOLIS, Sept. 14, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announces that the United States (U.S.) Food and Drug Administration (FDA) has approved its New Drug Application (NDA) for Pixclara® (floretyrosine F 18 or 18F-FET), an amino acid positron emission tomography (PET) drug for imaging gliomas (brain cancer).
Telix to Present at the Morgan Stanley 24th Annual Global Healthcare Conference and H.C. Wainwright 28th Annual Global Investment Conference
MELBOURNE, Australia and INDIANAPOLIS, Sept. 09, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) advises that Dr. Christian Behrenbruch, Managing Director and Group CEO and Kevin Richardson, CEO, Precision Medicine will present at the upcoming Morgan Stanley 24th Annual Global Healthcare Conference and at the H.C. Wainwright 28th Annual Global Investment Conference, both in New York, NY.
Telix Completes Enrollment in Phase 3 BiPASS Study, Aligns with FDA on NDA Pathway
MELBOURNE, Australia and INDIANAPOLIS, Sept. 02, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix”) today announced completion of patient enrollment in the Phase 3 BiPASS™ study of its commercial PSMA-PET1 imaging agents, Illuccix® (kit for the preparation of gallium Ga68 gozetotide injection) and Gozellix® (kit for the preparation of gallium Ga68 gozetotide injection) for prostate cancer imaging in the pre-biopsy setting. Telix has also aligned with the United States (U.S.) Food and Drug Administration (FDA) on a New Drug Application (NDA) pathway for BiPASS that, if approved, would support reimbursement as a new product and broaden patient access.
Telix Appoints David Gill as Chair
MELBOURNE, Australia and INDIANAPOLIS, Sept. 01, 2026 (GLOBE NEWSWIRE) -- Telix Pharmaceuticals Limited (ASX: TLX, NASDAQ: TLX, “Telix” or the “Company”) today announces that David Gill has been appointed Chair of the Board, effective immediately.
Telix Pharmaceuticals: Execution Is The Name Of The Game Here
Telix Pharmaceuticals has rebounded strongly, reaching profitability and guiding FY2026 revenue to $950–$970 million, driven by precision medicine sales. Key catalysts include imminent FDA decisions for TLX101-Px (brain tumor imaging) and resubmission plans for TLX250-Px (kidney cancer imaging). TLX's radiopharmaceutical pipeline advances with pivotal studies in prostate cancer diagnostics and therapeutics, supported by robust financials and a recent $600 million convertible bond raise.
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
Telix Pharmaceuticals Limited (TLX) Q2 2026 Earnings Call Transcript
